Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jeff Jonas, M.D., CEO of Tortugas Neuroscience, talks about the company's April 2026 launch and how in-licensed development assets were chosen. Jeff explains his strategy of chasing fast proof of safety and efficacy in humans, not animals, and talks about what product differentiation looks like in brain disorders, from adjusting indication targets to conducting head-to-head trials. He al...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Business Of Biotech
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.
Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
Get summaries like this every morning.
Free AI-powered recaps of Business Of Biotech and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.